Practice of prescribing antipsychotics in schizophrenia during 2013-2018 based on data from the National Health Fund
More details
Hide details
Instytut Psychiatrii i Neurologii, Warszawa
Pełnomocnik Ministra Zdrowia ds. reformy psychiatrii, Biuro ds. Pilotażu Narodowego Programu Ochrony Zdrowia Psychicznego
Departament Analiz i Strategii Ministerstwa Zdrowia, Warszawa
Śląski Uniwersytet Medyczny, Katowice
HTA Consulting, Kraków
Submission date: 2020-12-14
Final revision date: 2021-03-07
Acceptance date: 2021-03-08
Online publication date: 2022-08-31
Publication date: 2022-08-31
Psychiatr Pol 2022;56(4):751–766
The aim of the study was to analyse the prescribing pattern of antipsychotic drugs in patients with schizophrenia during the years 2013–2018.

Schizophrenia is analysed as one of the diseases with the highest rate of Disability-Adjusted Life Years – DALY. In this study, the unitary data of the National Health Fund (NFZ) reported in the years 2013–2018 were used. Adult patients were identified by their Personal Identification Number (PESEL), and the antipsychotics were identified by the European Article Number (EAN). The study included 209,334 adults who were diagnosed with F20 to F20.9 (according to ICD-10) and were prescribed at least one antipsychotic within a year. The active substances of prescribed antipsychotic medication have been divided into typical (first generation), atypical (second generation) and long-acting injectable antipsychotics (both first and second generation). The statistical analysis contains descriptive statistics for selected sections. A linear regression, one-way analysis of variance and t-test were used in the study. All statistical analyses were performed using R, version 3.6.1 and Microsoft Excel.

In the years 2013–2018, the number of patients in the public sector diagnosed with schizophrenia increased by 4%. The largest increase was recorded among persons diagnosed with other schizophrenia (F20.8). In the analysed years, the number of patients who were prescribed second-generation oral antipsychotics increased significantly as well as the number of patients who were prescribed long-acting antipsychotics, especially the secondgeneration agents (risperidone LAI, olanzapine LAI). The most prescribed first-generation antipsychotics included: perazine, levomepromazine and haloperidol with a downward trend for each; and the most common second-generation drugs included: olanzapine, aripiprazole and quetiapine. A noteworthy finding was an extremely high increase in the frequency of prescribing haloperidol in the form of depot.

Extending the study to include information on applied prescriptive practice in the private sector would provide a fuller picture of the studied phenomenon.